India, July 23 -- HAB Pharmaceuticals has set a target of Rs 3,000 crore revenue by 2030. What will be the key growth drivers?

HAB Pharma's revenue growth toward Rs 3,000 crore by 2030 will be driven by expanded manufacturing capacity, strengthened R&D capabilities, and portfolio diversification, including high-value speciality generics, semaglutide therapies, and phytochemical-based products. The company has invested in two major new plants, designed to expand production capacity and support future growth, and has also acquired a large existing facility in Dehradun of approximately 44,000 sq feet, which is planned for further development.

Among upcoming products, Vonoprazan is a notable addition; this proton pump inhibitor demonstrates...